Liquid BiOpsy, Lung and Colon Cancer in AndaluciA

Launched by FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN BIOMÉDICA ANDALUCÍA ORIENTAL · May 21, 2025

Keywords

ClinConnect Summary

The LOLA Project is an observational study in Andalusia that is looking at how using a large blood test (a liquid biopsy) called the xF Tempus panel in real life might change cancer care and costs. Researchers will use this test to look for genetic changes in metastatic non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (CRC) from blood samples. The main question is how often the test finds actionable variants—genetic changes that could influence treatment decisions—and how the test affects the way doctors work and the costs involved.

If you are eligible, you would be an adult (18+) with stage IV NSCLC or stage IV CRC who has not yet started systemic cancer treatment, and you would be able to consent to participate. You would have two blood tubes collected and sent to Tempus Labs for analysis with the xF Tempus assay. There is no experimental treatment given as part of the study; it is about testing use in real practice and measuring outcomes like turnaround time and resource use. The study plans to enroll about 500 people in Granada and is expected to run through roughly 2026, with ongoing monitoring by a safety and data oversight team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• General criteria:
• • More than 18 years old
• • Both genders
• • Ability to provide written informed consent
• Specific criteria:
• • NSCLC
• • Patients diagnosed with the 8th Edition of the Tumor, Node, Metastasis (TNM) staging system for Lung Cancer approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c)
• • Histologically confirmed NSCLC (adenocarcinoma)
• • Performance status of 0-2 (ECOG PS) ○ Estimated life expectancy ≥3 months
• • Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).
• • Smokers or Non-Smokers
• • CRC
• • Patients diagnosed with the Tumor, Node, Metastasis (TNM) staging system for Colorectal Cancer approved by the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c)
• • Histologically confirmed CRC (adenocarcinoma)
• • Performance status of 0-2 (ECOG PS)
• • Estimated life expectancy ≥3 months
• • Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).
• Exclusion Criteria:
• • General: History of any other cancer within the previous 5 years, except non-melanoma skin cancer
• • General: Absence of Informed consent. \> Pregnant or nursing women. \> Small cell lung cancer.